Reversion of neurovirulent mutations, recombination and high intra-host diversity in vaccine-derived poliovirus excreted by patients with primary immune deficiency.
Humans
Poliovirus
/ genetics
Poliovirus Vaccine, Oral
/ genetics
Recombination, Genetic
Mutation
Poliomyelitis
/ virology
Feces
/ virology
Male
Female
Virus Shedding
Genome, Viral
/ genetics
Genetic Variation
Primary Immunodeficiency Diseases
/ genetics
Child, Preschool
Evolution, Molecular
Child
Infant
Virulence
/ genetics
Phylogeny
intra‐host diversity
neurovirulent‐reverse mutations
recombination
vaccine‐derived poliovirus
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
Sep 2024
Sep 2024
Historique:
revised:
16
08
2024
received:
27
03
2024
accepted:
02
09
2024
medline:
23
9
2024
pubmed:
23
9
2024
entrez:
23
9
2024
Statut:
ppublish
Résumé
Patients with Primary immunodeficiency (PIDs) may be infected by Polioviruses (PVs), especially when vaccinated with live Oral Polio Vaccine before diagnosis. They may establish long-term shedding of divergent strains and may act as reservoirs of PV transmission. This study delved into the effect of the genetic evolution of complete PV genomes, from MHC class II-deficient patients, on the excretion duration and clinical outcomes. Stool samples from three PID patients underwent analysis for PV detection through inoculation on cell culture and real-time PCR, followed by VP1 partial sequencing and full genome sequencing using the Illumina technology. Our findings revealed a low number of mutations for one patient who cleared the virus, while two exhibited a high intra-host diversity favoring the establishment of severe outcomes. Neurovirulence-reverse mutations were detected in two patients, possibly leading to paralysis development. Furthermore, a recombination event, between type 3 Vaccine-Derived Poliovirus and Sabin-like1 (VDPV3/SL1), occurred in one patient. Our findings have suggested an association between intra-host diversity, recombination, prolonged excretion of the virus, and emergence of highly pathogenic strains. Further studies on intra-host diversity are crucial for a better understanding of the virus evolution as well as for the success of the Global Polio Eradication Initiative.
Substances chimiques
Poliovirus Vaccine, Oral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29918Subventions
Organisme : European project PHINDaccess: Strengthening Omics data analysis capacities in pathogen-host interaction
ID : 811034
Organisme : Tunisian Ministry of Higher Education and Scientifc Research
ID : LR20IPT10
Informations de copyright
© 2024 The Author(s). Journal of Medical Virology published by Wiley Periodicals LLC.
Références
Hsu CH, Kader M, Mahamud A, et al. Progress toward poliomyelitis eradication—Pakistan, January 2018–September 2019. MMWR Morb Mortal Wkly Rep. 2019;68(45):1029‐1033. doi:10.15585/mmwr.mm6845a5
Manyanga D, Masvikeni B, Daniel F. The experiences of using polio outbreak simulation exercises to strengthen national outbreaks preparedness and response plans in sub‐Saharan Africa. Pan Afr Med J. 2020;36(1):340.
CDC‐Centers for Disease Control and Prevention. Update on vaccine‐derived polioviruses worldwide, July 2009–March 2011. MMWR Morb Mortal Wkly Rep. 2011;60:846‐850.
Mohanty MC, Madkaikar MR, Desai M, et al. Natural clearance of prolonged VDPV infection in a child with primary immunodeficiency disorder. Front Immunol. 2019;10:1567. doi:10.3389/fimmu.2019.01567
Guo J, Bolivar‐Wagers S, Srinivas N, Holubar M, Maldonado Y. Immunodeficiency‐related vaccine‐derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication. Vaccine. 2015;33(10):1235‐1242. doi:10.1016/j.vaccine.2015.01.018
Kew OM, Wright PF, Agol VI, et al. Circulating vaccine‐derived polioviruses: current state of knowledge. Bull World Health Organ. 2004;82:16‐23.
Savolainen‐Kopra C, Blomqvist S. Mechanisms of genetic variation in polioviruses. Rev Med Virol. 2010;20(6):358‐371. doi:10.1002/rmv.663
Kirkegaard K, Baltimore D. The mechanism of RNA recombination in poliovirus. Cell. 1986;47(3):433‐443. doi:10.1016/0092-8674(86)90600-8
Rousset D, Rakoto‐Andrianarivelo M, Razafindratsimandresy R, et al. Recombinant vaccine–derived poliovirus in Madagascar. Emerging Infect Dis. 2003;9(7):885‐887. doi:10.3201/eid0907.020692
Pavlov DN, van Zyl WB, van Heerden J, et al. Prevalence of vaccine‐derived polioviruses in stools of immunodeficient children in South Africa. J Appl Microbiol. 2006;101(6):1367‐1379. doi:10.1111/j.1365-2672.2006.03020.x
Minor P. Vaccine‐derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine. 2009;27(20):2649‐2652. doi:10.1016/j.vaccine.2009.02.071
Kitamura K, Shimizu H. Outbreaks of circulating vaccine‐derived poliovirus in the world health organization Western pacific region, 2000–2021. Jpn J Infect Dis. 2022;75(5):JJID.2022.312. doi:10.7883/yoken.JJID.2022.312
Macklin G, Diop OM, Humayun A, et al. Update on immunodeficiency‐associated vaccine‐derived polioviruses—worldwide, July 2018–December 2019. MMWR Morb Mortal Wkly Rep. 2020;69(28):913‐917. doi:10.15585/mmwr.mm6928a4
Chouikha A, Rezig D, Driss N, et al. Circulation and molecular epidemiology of enteroviruses in paralyzed, immunodeficient and healthy individuals in Tunisia, a country with a polio‐free status for decades. Viruses. 2021;13(3):380. doi:10.3390/v13030380
Haddad‐Boubaker S, Ould‐Mohamed‐Abdallah MV, Ben‐Yahia A, Triki H. Recombinaison génétique chez le poliovirus vaccinal: étude comparative chez les souches excrétées en cours de vaccination par le vaccin poliomyélitique oral et les souches circulantes. Pathol Biol. 2010;58(6):420‐425. doi:10.1016/j.patbio.2009.01.004
Haddad‐Boubaker S, ben Yahia A, Bahri O, et al. Genetic features of polioviruses isolated in Tunisia, 1991–2006. J Clin Virol. 2008;41(2):81‐86. doi:10.1016/j.jcv.2007.10.002
Driss N, Mellouli F, ben Yahia A, et al. Sequential asymptomatic enterovirus infections in a patient with major histocompatibility complex class II primary immunodeficiency. J Clin Microbiol. 2014;52(9):3486‐3489. doi:10.1128/JCM.01122-14
Driss N, Ben‐Mustapha I, Mellouli F, et al. High susceptibility for enterovirus infection and virus excretion features in Tunisian patients with primary immunodeficiencies. Clin Vaccine Immunol. 2012;19(10):1684‐1689. doi:10.1128/CVI.00293-12
Global Polio Eradication Initiative Updates on ITD molecular testing. Global Polio Eradication Initiative; 2020. https://polioeradication.org/wp-content/uploads/2020/01/GP2-Updates-on-ITD-molecular-testing.pdf
Steven Oberste M, Pallansch MA. Enteroviruses and parechoviruses. Clinical virology manual. ASM Press; 2016:277‐292. doi:10.1128/9781555819156.ch20
Kilpatrick DR, Iber JC, Chen Q, et al. Poliovirus serotype‐specific VP1 sequencing primers. J Virol Methods. 2011;174(1‐2):128‐130. doi:10.1016/j.jviromet.2011.03.020
Nextera DNA Library Prep Reference Guide (15027987). https://support.illumina.com/content/dam/illumina-support/documents/documentation/chemistry_documentation/samplepreps_nextera/nexteradna/nextera-dna-library-prep-reference-guide-15027987-01.pdf
Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra‐fast all‐in‐one FASTQ preprocessor. Bioinformatics. 2018;34(17):i884‐i890. doi:10.1093/bioinformatics/bty560
Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA‐MEM. arXiv preprint arXiv:1303.3997. 2013.
Grubaugh ND, Gangavarapu K, Quick J, et al. An amplicon‐based sequencing framework for accurately measuring intrahost virus diversity using PrimalSeq and iVar. Genome Biol. 2019;20(1):8. doi:10.1186/s13059-018-1618-7
Lole KS, Bollinger RC, Paranjape RS, et al. Full‐length human immunodeficiency virus type 1 genomes from subtype C‐infected seroconverters in India, with evidence of intersubtype recombination. J Virol. 1999;73(1):152‐160. doi:10.1128/JVI.73.1.152-160.1999
Kumar S, Stecher G, Tamura K. MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol Biol Evol. 2016;33(7):1870‐1874. doi:10.1093/molbev/msw054
Lefort V, Longueville J‐E, Gascuel O. SMS: smart model selection in PhyML. Mol Biol Evol. 2017;34(9):2422‐2424. doi:10.1093/molbev/msx149
McKenna A, Hanna M, Banks E, et al. The genome analysis toolkit: a MapReduce framework for analyzing next‐generation DNA sequencing data. Genome Res. 2010;20(9):1297‐1303. doi:10.1101/gr.107524.110
Wickham H. ggplot2. Springer New York; 2009. doi:10.1007/978-0-387-98141-3
Westrop GD, Wareham KA, Evans DM, et al. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J Virol. 1989;63(3):1338‐1344. doi:10.1128/jvi.63.3.1338-1344.1989
Nomoto A, Omata T, Toyoda H, et al. Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome. Proc Natl Acad Sci USA. 1982;79(19):5793‐5797. doi:10.1073/pnas.79.19.5793
Gong P, Peersen OB. Structural basis for active site closure by the poliovirus RNA‐dependent RNA polymerase. Proc Natl Acad Sci USA. 2010;107(52):22505‐22510. doi:10.1073/pnas.1007626107
Stanway G, Hughes PJ, Mountford RC, et al. Comparison of the complete nucleotide sequences of the genomes of the neurovirulent poliovirus P3/Leon/37 and its attenuated Sabin vaccine derivative P3/Leon 12a1b. Proc Natl Acad Sci USA. 1984;81(5):1539‐1543. doi:10.1073/pnas.81.5.1539
Pollard SR, Dunn G, Cammack N, Minor PD, Almond JW. Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine. J Virol. 1989;63(11):4949‐4951. doi:10.1128/jvi.63.11.4949-4951.1989
Christodoulou C, Colbere‐Garapin F, Macadam A, et al. Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature. J Virol. 1990;64(10):4922‐4929. doi:10.1128/jvi.64.10.4922-4929.1990
Fayaz F, Sharafian S, Tavakol M. Incidence of poliovirus infection in patients with severe combined immunodeficiency (SCID). Immunol Genet J. 2022;4:95‐100. doi:10.18502/igj.v4i2.9985
Bittles AH, Black ML. Consanguineous marriage and human evolution. Annu Rev Anthropol. 2010;39(1):193‐207. doi:10.1146/annurev.anthro.012809.105051
elHawary RE, Mauracher AA, Meshaal SS, et al. MHC‐II deficiency among Egyptians: novel mutations and unique phenotypes. J Allergy Clin Immunol Pract. 2019;7(3):856‐863. doi:10.1016/j.jaip.2018.07.046
Shaghaghi M, Shahmahmoodi S, Nili A, et al. Vaccine‐derived poliovirus infection among patients with primary immunodeficiency and effect of patient screening on disease outcomes, Iran. Emerging Infect Dis. 2019;25(11):2005‐2012. doi:10.3201/eid2511.190540
Mohanty MC, Madkaikar MR, Desai M, et al. Poliovirus excretion in children with primary immunodeficiency disorders, India. Emerging Infect Dis. 2017;23(10):1664‐1670. doi:10.3201/eid2310.170724
Shaghaghi M, Shahmahmoodi S, Abolhassani H, et al. Vaccine‐Derived polioviruses and children with primary immunodeficiency, Iran, 1995–2014. Emerging Infect Dis. 2016;22(10):1712‐1719. doi:10.3201/eid2210.151071
Combelas N, Holmblat B, Joffret M‐L, Colbère‐Garapin F, Delpeyroux F. Recombination between poliovirus and coxsackie A viruses of species C: a model of viral genetic plasticity and emergence. Viruses. 2011;3(8):1460‐1484. doi:10.3390/v3081460
Yang C‐F, Chen H‐Y, Jorba J, et al. Intratypic recombination among lineages of type 1 vaccine‐derived poliovirus emerging during chronic infection of an immunodeficient patient. J Virol. 2005;79(20):12623‐12634. doi:10.1128/JVI.79.20.12623-12634.2005
Pfeiffer JK. Innate host barriers to viral trafficking and population diversity. Adv Virus Res. 2010;77:85‐118. doi:10.1016/B978-0-12-385034-8.00004-1
Jary A, Leducq V, Malet I, et al. Evolution of viral quasispecies during SARS‐CoV‐2 infection. Clin Microbiol Infect. 2020;26(11):1560.e1‐1560.e4. doi:10.1016/j.cmi.2020.07.032
Martín J, Dunn G, Hull R, Patel V, Minor PD. Evolution of the sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637‐Day period of virus excretion. J Virol. 2000;74(7):3001‐3010. doi:10.1128/JVI.74.7.3001-3010.2000
alKhatib HA, Benslimane FM, Elbashir IE, et al. Within‐host diversity of SARS‐CoV‐2 in COVID‐19 patients with variable disease severities. Front Cell Infect Microbiol. 2020;10:575613. doi:10.3389/fcimb.2020.575613
Voloch CM, da Silva Francisco Jr. R, de Almeida LGP, et al. Intra‐host evolution during SARS‐CoV‐2 prolonged infection. Virus Evol. 2021;7(2):veab078. doi:10.1093/ve/veab078
Karamitros T, Papadopoulou G, Bousali M, Mexias A, Tsiodras S, Mentis A. SARS‐CoV‐2 exhibits intra‐host genomic plasticity and low‐frequency polymorphic quasispecies. J Clin Virol. 2020;131:104585. doi:10.1016/j.jcv.2020.104585